InvestorsHub Logo
Followers 38
Posts 7607
Boards Moderated 2
Alias Born 09/06/2014

Re: slopak post# 91896

Thursday, 01/05/2017 9:14:35 AM

Thursday, January 05, 2017 9:14:35 AM

Post# of 337135
ActiPatch sales history in the UK will be repeated in the US.

They have opioids in the UK. The ActiPatch doesn't cure opioid addiction. The ActiPatch is a low-powered PEMF device that provides some benefit to some people -- not enough benefit to make it a retail success as proven in the UK.

Unless BIEL can lower their price to, say, $15. If a company could lower its price to $15 they might hit the sweet spot in the Demand Curve and turn a profit selling the ActiPatch OTC. Possibly. A meager profit, but a profit nonetheless.

It won't be BIEL though, IMO. BIEL is toast.

I see nothing here to LOL about.